Amicus Therapeutics - Articles and news items

Amicus submits EU marketing authorisation application for Fabry monotherapy Galafold

Industry news / 3 June 2015 / Victoria White

Amicus Therapeutics has submitted a MAA to request full approval in the EU of Galafold for Fabry patients who have amenable genetic mutations…

GlaxoSmithKline logo

Top-line six-month primary treatment period results from first Phase III Fabry monotherapy study

Industry news, News / 19 December 2012 / GlaxoSmithKline

Six-month primary treatment period results…

GlaxoSmithKline logo

GlaxoSmithKline and Amicus Therapeutics expand Fabry disease collaboration

Industry news, News / 17 July 2012 / GlaxoSmithKline

Fabry products to be commercialised by Amicus in US and by GSK ex-US…

GlaxoSmithKline logo

GlaxoSmithKline and Amicus Therapeutics commence second phase III study of Amigal™ for Fabry disease

Industry news, News / 12 September 2011 / GSK

The first patient has commenced dosing in a Phase III global registration study…


The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...